Pharmacogenetic Determinants Of Treatment Response In Children

St. Jude Children's Research Hospital

Status: Enrolling

Conditions: Children Being Treated for Catastrophic Illness; All Malignancies

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT00730678

R37CA036401 (U.S. NIH Grant/Contract)

R01CA036401 (U.S. NIH Grant/Contract)

P50GM115279 (U.S. NIH Grant/Contract)

R01CA264837 (U.S. NIH Grant/Contract)

R01GM118578 (U.S. NIH Grant/Contract)

NCI-2021-09904 (Registry Identifier)

PGEN5

R35GM141947 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

To investigate whether genetic polymorphisms in genes encoding proteins involved in the metabolism or effects of drugs or environmental agents influence the disposition or effects of these xenobiotic substrates. To investigate the nature of heritability and the genetic basis of pharmacogenetic traits by studying family members of individuals with specific genotypes.

Full description

Pharmacogenetics is that discipline devoted to elucidating the genetic determinants of drug response. Particularly in the area of drug metabolism, many genes exhibit genetic polymorphism; that is, a stable percentage of the population (which generally differs by ethnic group) is deficient in the functional expression of the enzyme involved, and the deficiency is typically inherited as an autosomal recessive trait. With currently known polymorphisms in drug metabolism, the percentage of homozygous deficient individuals ranges from 0.3% to as many as 90% of the population, depending on the enzyme and the ethnic group.

Our prior studies have revealed multigenic pharmacogenetic models that are significantly predictive of various drug response phenotypes (e.g., drug resistance, drug clearance, drug toxicity, disease response) in children with ALL. The large number of candidate loci and the relatively small number of patients illustrate the fact that larger sample sizes are required to definitively establish these polygenic models. The fact that there were significant race/genotype interactions, such that predictions differed in whites vs blacks, highlights the need for adequate numbers of patients within racial and ethnic groups to allow differential analysis of genotypic predictors after adjusting for confounding demographic factors in pharmacogenetic studies via stratified design and analyses.

Enrollment: 8,800 estimated patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Any patients under evaluation/treatment at St. Jude Children's Research Hospital (SJCRH)
• Parents or family members of St. Jude patients
• Non patient volunteers
• All study subjects must provide informed consent for participation
• Assent/Consent of the patient (parent) must be provided prior to attempts made by investigators to enroll a family member of a SJCRH patient

Exclusion Criteria:

Trial design

8,800 participants in 1 patient group

All Participants

Description:

All participants enrolled on this study will have blood drawn for genetic testing.